查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1308753

到 2030 年神經修復和再生市場預測 - 按產品、按手術、按應用、按最終用戶、按地區進行全球分析

Nerve Repair and Regeneration Market Forecasts to 2030 - Global Analysis By Product, Surgery, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的複合年增長率為 14.1%，全球神經修復和再生市場預計 2023 年將達到 89.4 億美元，2030 年將達到 225.2 億美元。

可用於神經修復和再生的產品包括神經刺激器、神經調節器和生物材料裝置。 這些設備用於治療創傷性和神經退行性疾病，如阿爾茨海默病、帕金森病、肌萎縮側索硬化症、多發性硬化症和多系統萎縮症。 由於大腦、脊髓和周圍神經脆弱且容易受損，因此它們與肌肉和器官溝通的能力可能會受到損害。 這些損傷可以通過神經修復和再生產品來修復。

據 2021 年 7 月出版的《柳葉刀全球健康》雜誌報導，約有 5000 萬人患有癲癇症。 據該雜誌報導，印度約有 10-1200 萬人被診斷患有癲癇症。

市場動態：

驅動程序

世界發展中國家

印度、中國和巴西等新興國家可能在預測期內為市場進入者提供顯著的增長前景。 龐大的人口基數，尤其是印度和中國的人口基數，預計將成為進入該市場的公司的主要吸引力。 這是由於阿爾茨海默病、帕金森病和癲癇等神經系統疾病的患病率不斷增加所致。 據世界銀行稱，這些國家的醫療保健支出正在增加，支持醫院和門診手術設施的增加。 由於醫院和門診手術設施是神經修復和再生產品的主要最終消費者，這被認為是市場擴張的良好指標。

限制

臨床結果不確定

儘管神經病理生理學和實驗表明有希望的神經治療方式取得了重大進展，但周圍神經撕脫、擠壓和爆炸傷病例的臨床結果仍然難以捉摸。這仍然很困難。 儘管神經損傷後積極的康復可能會減少神經損傷和創傷後肌肉廢用性萎縮的發生率，但肌肉靶向去神經萎縮是神經再生努力的嚴重障礙。 即使神經再生效果最好，由於缺乏可行的神經肌肉接頭 (NMJ) 和肌肉靶標，功能結果也很差。

機會

人口老齡化

世界發達地區的老年人口正在增加。 中風、神經病、阿爾茨海默病和帕金森病等神經系統疾病在老年人群中更為普遍。 老年人口由於其高易感性而佔患者總數的很大一部分。 因此，該群體不斷增長的人口將確保對神經修復和再生用於治療神經系統疾病的持續增長的需求。

威脅

神經刺激器和神經調節器很昂貴。

使用神經調節劑的初始成本很大。 由於這些設備成本高昂，即使在負擔得起的地區，它們也可能被不公平地使用。 儘管神經刺激對患者和保險公司來說初始成本很高，但對治療的長期擔憂給國家醫療保健系統帶來了較小的成本。 此外，保險公司承保部分治療，但不是全部。 這會影響醫院的整體預算。 因此，這一因素很可能對市場產生相當大的影響。

COVID-19 的影響：

COVID-19疫情對神經修復和再生市場產生了不利影響。 這是因為世界各國政府實施的社會疏遠措施嚴重限制了醫院和醫療服務。 此外，COVID-19 疫情嚴重影響了全球醫院對非 COVID-19 患者的綜合護理能力。 由於許多醫院和診所仍然關閉，神經修復和重建手術的需求正在下降。

幹細胞治療細分市場將在預測期內規模最大：

由於神經系統疾病發生頻率的增加、對有效治療的需求不斷增長、政府的各種舉措以及生物材料研究的批准，預計幹細胞治療領域將在預測期內佔據最大份額。 此外，幹細胞可通過替換分化後有缺陷、死亡或垂死的腦細胞來治療神經退行性疾病。

預計酒店業在預測期內的複合年增長率最高：

酒店業在預測期內的複合年增長率最高。 神經系統疾病發病率的上升、發展中國家醫院數量的增加、神經流行病學的增長和發展都是醫院領域崛起的重要驅動力。 然而，持續監測是通過提供有關患者生理狀態的更多信息來幫助醫療和護理人員的好方法。 這被認為是市場增長的有利指標，因為酒店業是神經修復和再生產品的主要最終用戶。

份額最大的地區：

在預測期內，神經退行性和神經發育疾病、中風和創傷性腦損傷的患病率不斷上升，先進醫療基礎設施的採用不斷增加，以及患者對神經修復和再生方法的認識不斷提高，將導致北美主導的神經修復和再生市場份額。 此外，該領域大型競爭對手的存在和頻繁的產品開發也有望在市場增長中發揮重要作用。

複合年增長率最高的地區：

由於患者意識的提高、政府的支持措施、未滿足的醫療需求的普遍存在以及新技術的出現，預計亞太地區在整個預測期內將呈現最高的複合年增長率。 該地區國家的經濟增長、神經系統疾病發病率的上升、生活水平的提高、對優質醫療保健的需求不斷增加以及醫療保健支出的增加將在整個預測期內推動該地區的市場。 此外，中國、印度、日本、澳大利亞和新加坡也對該地區的增長做出了重大貢獻。

主要進展：

2022 年 10 月，Phageneis 的 Phagenyx 神經刺激系統獲得美國 FDA 新批准，該系統使用電咽刺激來恢復中風後嚴重吞嚥困難患者的吞嚥控制。

2022 年 8 月，雅培的採用 FlexBurst 療法的 ProClaim plus 脊髓刺激系統獲得美國 FDA 批准。 FlexBurst 360 療法是 Abbott 專有的下一代 BurstDR 刺激療法，可覆蓋軀乾和四肢的六個區域的疼痛。

報告內容

  • 區域和國家級市場份額評估
  • 給新進入者的戰略建議
  • 涵蓋 2021 年、2022 年、2023 年、2026 年和 2030 年的市場數據
  • 市場趨勢（驅動因素、干擾因素、機遇、威脅、挑戰、投資機會、建議）
  • 根據市場預測提出關鍵業務領域的戰略建議
  • 繪製主要總體趨勢的競爭格局
  • 公司簡介，包括詳細的戰略、財務狀況和最新發展
  • 供應鏈趨勢映射最新技術趨勢

免費定制服務：

訂閱此報告的客戶將獲得以下免費自定義選項之一：

  • 公司簡介
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要公司的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家/地區的市場估計/預測/複合年增長率（注：基於可行性檢查）
  • 競爭基準測試
    • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 執行摘要
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究來源
    • 二手研究來源
    • 先決條件

第三章市場趨勢分析

  • 驅動程序
  • 制約因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠肺炎 (COVID-19) 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間存在敵對關係

第五章全球神經修復和再生市場：按產品

  • 生物材料
    • 神經包裹
    • 神經連接器
    • 神經保護器
    • 神經導管
  • 神經刺激和神經調節劑
    • 內神經刺激器
      • □神經刺激 (SNS)
      • 深部腦刺激 (DBS)
      • 迷走神經刺激 (VNS)
      • 脊髓刺激 (SCS)
      • 胃電刺激 (GES)
    • 外部神經刺激器
      • 電呼吸刺激 (RES) 設備
      • 經顱磁刺激 (TMS) 裝置
      • 經皮神經電刺激 (TENS) 裝置
  • 其他產品

第 6 章：神經修復和再生的全球市場：通過手術

  • 神經調節手術
  • 幹細胞療法
  • 神經移植
  • 直接神經病變

第 7 章：全球神經修復和再生市場：按應用分類

  • 神經移植
    • 異種移植
    • 自體移植物
    • 同種異體移植物
  • 神經刺激和神經調節手術
    • 內神經刺激和神經調節手術
    • 體外神經刺激和神經調節手術
  • 幹細胞療法
  • 直接神經修復/神經切除術
    • 團體筋膜修復
    • 硬膜外修復術
    • 神經周圍修復
  • 用於神經修復和再生的生物材料
    • 直接神經修復/神經切除術
      • 團體筋膜修復
      • 神經周圍修復
      • 硬膜外修復術
  • 其他用途

第 8 章：全球神經修復和再生市場：按最終用戶劃分

  • 門診手術中心
  • 診所
  • 醫院
  • 其他最終用戶

第 9 章：全球神經修復和再生市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 亞太地區其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東和非洲地區

第 10 章主要進展

  • 合同、合作夥伴關係、聯盟和合資企業
  • 收購與合併
  • 推出新產品
  • 業務擴展
  • 其他關鍵策略

第 11 章公司簡介

  • Polyganics
  • Nevro Corp.
  • Soterix Medical, Inc.
  • Kerimedical
  • Livanova, Plc.
  • Integra Lifesciences
  • Collagen Matrix, Inc.
  • Axogen, Inc.
  • Neuropace, Inc.
  • Aleva Neurotherapeutics
  • Boston Scientific Corporation
  • Baxter International, Inc.
  • Synapse Biomedical, Inc.
  • Medtronic, Plc.
  • Abbott Laboratories
Product Code: SMRC23453

According to Stratistics MRC, the Global Nerve Repair and Regeneration Market is accounted for $8.94 billion in 2023 and is expected to reach $22.52 billion by 2030 growing at a CAGR of 14.1% during the forecast period. Neurostimulation, neuromodulators, and biomaterial devices are among the products available for nerve repair and regeneration. These devices are used to treat traumatic or neurodegenerative diseases such as Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, multiple sclerosis, and multiple system atrophy. Because the brain, spinal cord, and peripheral nerves are delicate and readily damaged, they can impair the brain's capacity to communicate with muscles and organs. These damages are repaired by nerve repair and regeneration products.

According to the journal The Lancet Global Health published in July 2021, it was reported that around 50 million people suffer from epilepsy, globally. As per the same source, it was also reported that around 10-12 million people are diagnosed with epilepsy, in India.

Market Dynamics:

Driver:

Globally developing nations

Developing countries such as India, China, and Brazil are likely to provide market participants with substantial growth prospects over the projection period. The massive population base, particularly in India and China, is projected to be a big draw for enterprises approaching this market. This is aided by the increasing prevalence of neurological illnesses such as Alzheimer's, Parkinson's, and epilepsy. According to the World Bank, healthcare expenditure in these nations is increasing, which is supporting the rise of hospitals and ambulatory surgery facilities. As hospitals and ambulatory surgery centers are key end consumers of nerve repair and regeneration products, this is considered a good indicator for market expansion.

Restraint:

Uncertain clinical outcomes

Despite significant advances in neuropathophysiology and experimental indications of promising neurotherapies, obtaining clinical outcomes in cases of avulsion, crush, or blast injuries to peripheral nerves remains difficult. Although vigorous rehabilitation after a nerve injury may reduce the incidence of muscular disuse atrophy after a nerve transaction or trauma, denervation atrophy of muscle targets is a serious impediment to nerve regeneration initiatives. Even the best neuroregeneration outcomes can be harmed by the absence of a viable neuromuscular junction (NMJ) or muscle target, resulting in poor functional outcomes.

Opportunity:

Growth of geriatric population

The world's developed regions have witnessed a growth in the geriatric population. Neurologic illnesses such as stroke, neuropathy, Alzheimer's disease, and Parkinson's disease are more prevalent among the elderly population. Geriatrics make up a significant portion of the entire patient pool due to their higher susceptibility. As a result, the sustained and increased need for nerve repair and regeneration for the treatment of neurological illnesses will be ensured by the rise of this segment of the population.

Threat:

Neurostimulation and neuromodulation devices are expensive

The use of neuromodulation devices has a substantial upfront cost. Because of the high cost of these devices, they may be used disproportionately in geographical locations with varying levels of financial resources. While neurostimulation has a high up-front cost for patients and insurance companies, the costs to the nation's healthcare system from long-term concerns with the treatment are insignificant. Furthermore, insurance companies cover some but not all therapy. This has an impact on the hospital's overall budget. As a result, this element would have a considerable impact on the market.

COVID-19 Impact:

The COVID-19 epidemic had a detrimental influence on the nerve repair and regeneration market because hospital and healthcare services were drastically limited due to social distancing measures implemented by governments worldwide. Furthermore, the COVID-19 pandemic had a significant impact on the functioning of general hospital treatment for non-COVID-19 patients in hospitals around the world. The need for nerve repair and regeneration procedures is decreasing as many hospitals and clinics remain closed due to the lockdown.

The stem cell therapy segment is expected to be the largest during the forecast period:

Because of the increasing frequency of neurological illnesses as well as the growing desire for effective treatment alternatives, different government efforts, and approvals to perform research investigations of biomaterials, the Stem Cell Therapy segment is poised to hold the largest share throughout the projection period. Additionally, following differentiation, stem cells could be used to treat neurodegenerative illnesses by replacing defective, dead, or dying brain cells.

The hospitals segment is expected to have the highest CAGR during the forecast period:

The hospital segment commanded the highest CAGR throughout the projected period. The rising frequency of neurological illnesses, the increasing number of hospitals in developing countries, and the growth and development of neuroepidemiology have all been important driving factors in the hospital segment's rise. However, continuous monitoring is an outstanding approach that assists medical and nursing staff by providing more information about the patient's physiologic condition. As hospitals are the primary end-users of nerve repair and regeneration products, this is considered a favorable indicator for market growth.

Region with largest share:

During the forecast period, North America dominated the nerve repair and regeneration market share, owing to an increase in the prevalence of neurodegenerative and neurodevelopmental diseases, stroke, and traumatic brain injuries; an increase in the adoption of advanced healthcare infrastructure; and an increase in patient awareness of nerve repair and regeneration modalities. Furthermore, the presence of significant market competitors and frequent product developments in this area are projected to play an important role in market growth.

Region with highest CAGR:

Due to increased patient awareness, supportive government initiatives, the prevalence of unmet medical requirements, and the emergence of novel technologies, Asia-Pacific is expected to have the highest CAGR throughout the forecast period. Economic growth in this region's countries, the rising frequency of neurologic illnesses, the rising standard of living, the rising demand for outstanding medical care, and rising healthcare spending will drive the region's market throughout the projection period. Moreover, China, India, Japan, Australia, and Singapore are the primary contributors to the region's growth.

Key players in the market

Some of the key players in Nerve Repair and Regeneration market include Polyganics , Nevro Corp., Soterix Medical, Inc., Kerimedical, Livanova, Plc., Integra Lifesciences, Collagen Matrix, Inc., Axogen, Inc., Neuropace, Inc., Aleva Neurotherapeutics, Boston Scientific Corporation, Baxter International, Inc., Synapse Biomedical, Inc., Medtronic, Plc. and Abbott Laboratories.

Key Developments:

In October 2022, Phageneis received United States FDA de novo approval for the Phagenyx neurostimulation system, which uses pharyngeal electrical stimulation to restore swallowing control in patients with severe dysphagia post-stroke.

In August 2022, Abbott received United States FDA approval for the ProClaim plus spinal cord stimulation system featuring FlexBurst therapy. The next generation of Abbott's proprietary BurstDR stimulation, FlexBurst 360 therapy, offers pain coverage across six areas of the trunk and limbs.

Products Covered:

  • Biomaterials
  • Neurostimulation and Neuromodulation Devices
  • Other Products

Surgeries Covered:

  • Neuromodulation Surgery
  • Stem Cell Therapy
  • Nerve Grafting
  • Direct Neuropathy

Applications Covered:

  • Nerve Grafting
  • Neurostimulation and Neuromodulation Surgeries
  • Stem Cell Therapy
  • Direct Nerve Repair/Neurorrhaphy
  • Nerve Repair & Regeneration Biomaterials
  • Other Applications

End Users Covered:

  • Ambulatory Surgery Centers
  • Clinics
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nerve Repair and Regeneration Market, By Product

  • 5.1 Introduction
  • 5.2 Biomaterials
    • 5.2.1 Nerve Wraps
    • 5.2.2 Nerve Connectors
    • 5.2.3 Nerve Protectors
    • 5.2.4 Nerve Conduits
  • 5.3 Neurostimulation and Neuromodulation Devices
    • 5.3.1 Internal Neurostimulation Devices
      • 5.3.1.1 Sacral Nerve Stimulation (SNS)
      • 5.3.1.2 Deep Brain Stimulation (DBS)
      • 5.3.1.3 Vagus Nerve Stimulation (VNS)
      • 5.3.1.4 Spinal Cord Stimulation (SCS)
      • 5.3.1.5 Gastric Electrical Stimulation (GES)
    • 5.3.2 External Neurostimulation Devices
      • 5.3.2.1 Respiratory Electric Stimulation (RES) Devices
      • 5.3.2.2 Transcranial Magnetic Stimulation (TMS) Devices
      • 5.3.2.3 Transcutaneous Electrical Nerve Stimulation (TENS) Devices
  • 5.4 Other Products

6 Global Nerve Repair and Regeneration Market, By Surgery

  • 6.1 Introduction
  • 6.2 Neuromodulation Surgery
  • 6.3 Stem Cell Therapy
  • 6.4 Nerve Grafting
  • 6.5 Direct Neuropathy

7 Global Nerve Repair and Regeneration Market, By Application

  • 7.1 Introduction
  • 7.2 Nerve Grafting
    • 7.2.1 Xenografts
    • 7.2.2 Autografts
    • 7.2.3 Allografts
  • 7.3 Neurostimulation and Neuromodulation Surgeries
    • 7.3.1 Internal Neurostimulation and Neuromodulation Surgeries
    • 7.3.2 External Neurostimulation and Neuromodulation Surgeries
  • 7.4 Stem Cell Therapy
  • 7.5 Direct Nerve Repair/Neurorrhaphy
    • 7.5.1 Group Fascicular Repair
    • 7.5.2 Epineural Repair
    • 7.5.3 Perineural Repair
  • 7.6 Nerve Repair & Regeneration Biomaterials
    • 7.6.1 Direct Nerve Repair/Neurorrhaphy
      • 7.6.1.1 Group Fascicular Repair
      • 7.6.1.2 Perineural Repair
      • 7.6.1.3 Epineural Repair
  • 7.7 Other Applications

8 Global Nerve Repair and Regeneration Market, By End User

  • 8.1 Introduction
  • 8.2 Ambulatory Surgery Centers
  • 8.3 Clinics
  • 8.4 Hospitals
  • 8.5 Other End Users

9 Global Nerve Repair and Regeneration Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Polyganics
  • 11.2 Nevro Corp.
  • 11.3 Soterix Medical, Inc.
  • 11.4 Kerimedical
  • 11.5 Livanova, Plc.
  • 11.6 Integra Lifesciences
  • 11.7 Collagen Matrix, Inc.
  • 11.8 Axogen, Inc.
  • 11.9 Neuropace, Inc.
  • 11.10 Aleva Neurotherapeutics
  • 11.11 Boston Scientific Corporation
  • 11.12 Baxter International, Inc.
  • 11.13 Synapse Biomedical, Inc.
  • 11.14 Medtronic, Plc.
  • 11.15 Abbott Laboratories

List of Tables

  • Table 1 Global Nerve Repair and Regeneration Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Nerve Repair and Regeneration Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Nerve Repair and Regeneration Market Outlook, By Biomaterials (2021-2030) ($MN)
  • Table 4 Global Nerve Repair and Regeneration Market Outlook, By Nerve Wraps (2021-2030) ($MN)
  • Table 5 Global Nerve Repair and Regeneration Market Outlook, By Nerve Connectors (2021-2030) ($MN)
  • Table 6 Global Nerve Repair and Regeneration Market Outlook, By Nerve Protectors (2021-2030) ($MN)
  • Table 7 Global Nerve Repair and Regeneration Market Outlook, By Nerve Conduits (2021-2030) ($MN)
  • Table 8 Global Nerve Repair and Regeneration Market Outlook, By Neurostimulation and Neuromodulation Devices (2021-2030) ($MN)
  • Table 9 Global Nerve Repair and Regeneration Market Outlook, By Internal Neurostimulation Devices (2021-2030) ($MN)
  • Table 10 Global Nerve Repair and Regeneration Market Outlook, By External Neurostimulation Devices (2021-2030) ($MN)
  • Table 11 Global Nerve Repair and Regeneration Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 12 Global Nerve Repair and Regeneration Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 13 Global Nerve Repair and Regeneration Market Outlook, By Neuromodulation Surgery (2021-2030) ($MN)
  • Table 14 Global Nerve Repair and Regeneration Market Outlook, By Stem Cell Therapy (2021-2030) ($MN)
  • Table 15 Global Nerve Repair and Regeneration Market Outlook, By Nerve Grafting (2021-2030) ($MN)
  • Table 16 Global Nerve Repair and Regeneration Market Outlook, By Direct Neuropathy (2021-2030) ($MN)
  • Table 17 Global Nerve Repair and Regeneration Market Outlook, By Application (2021-2030) ($MN)
  • Table 18 Global Nerve Repair and Regeneration Market Outlook, By Nerve Grafting (2021-2030) ($MN)
  • Table 19 Global Nerve Repair and Regeneration Market Outlook, By Xenografts (2021-2030) ($MN)
  • Table 20 Global Nerve Repair and Regeneration Market Outlook, By Autografts (2021-2030) ($MN)
  • Table 21 Global Nerve Repair and Regeneration Market Outlook, By Allografts (2021-2030) ($MN)
  • Table 22 Global Nerve Repair and Regeneration Market Outlook, By Neurostimulation and Neuromodulation Surgeries (2021-2030) ($MN)
  • Table 23 Global Nerve Repair and Regeneration Market Outlook, By Internal Neurostimulation and Neuromodulation Surgeries (2021-2030) ($MN)
  • Table 24 Global Nerve Repair and Regeneration Market Outlook, By External Neurostimulation and Neuromodulation Surgeries (2021-2030) ($MN)
  • Table 25 Global Nerve Repair and Regeneration Market Outlook, By Stem Cell Therapy (2021-2030) ($MN)
  • Table 26 Global Nerve Repair and Regeneration Market Outlook, By Direct Nerve Repair/Neurorrhaphy (2021-2030) ($MN)
  • Table 27 Global Nerve Repair and Regeneration Market Outlook, By Group Fascicular Repair (2021-2030) ($MN)
  • Table 28 Global Nerve Repair and Regeneration Market Outlook, By Epineural Repair (2021-2030) ($MN)
  • Table 29 Global Nerve Repair and Regeneration Market Outlook, By Perineural Repair (2021-2030) ($MN)
  • Table 30 Global Nerve Repair and Regeneration Market Outlook, By Nerve Repair & Regeneration Biomaterials (2021-2030) ($MN)
  • Table 31 Global Nerve Repair and Regeneration Market Outlook, By Direct Nerve Repair/Neurorrhaphy (2021-2030) ($MN)
  • Table 32 Global Nerve Repair and Regeneration Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 33 Global Nerve Repair and Regeneration Market Outlook, By End User (2021-2030) ($MN)
  • Table 34 Global Nerve Repair and Regeneration Market Outlook, By Ambulatory Surgery Centers (2021-2030) ($MN)
  • Table 35 Global Nerve Repair and Regeneration Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 36 Global Nerve Repair and Regeneration Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 37 Global Nerve Repair and Regeneration Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.